Evolving Evidence and Treatment Strategies in Low Grade Serous Ovarian Cancer (LGSOC)
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Evolving Evidence and Treatment Strategies in Low‑Grade Serous Ovarian Cancer (LGSOC) Industry Supported Symposium being presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Saturday, June 13, 2026 from 12:00 pm – 1:15 pm ET.
This educational activity is supported by an independent medical education grant from Verastem Oncology.
Course Description
This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of antibody–drug conjugates (ADCs) in low‑grade serous ovarian cancer, MEK inhibitors, and the significance of KRAS mutations. Additionally, the course will address the management of adverse events, dose modifications, and strategies to support patients experiencing treatment‑related reactions. A discussion of biomarkers and considerations for first‑line management of recurrent disease will help clinicians make informed, evidence‑based decisions.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Current competitive landscape, new indication, Folate Receptor Alpha Data
- What’s next including the future of ADCs in Low Grade Serous Ovarian Cancer, MEK Inhibitors and understanding the KRAS mutated gene
- Averse Events and helping patients with adverse reactions and dose modifications.
- Biomarkers and Understanding first line management of recurrent disease
Faculty
Brian Slomovitz, MD (moderator)
Mount Sinai Medical Center
Jubilee Brown, MD
Atrium Health Wak Forest Baptist Comprehensive Cancer Center
Agenda
Evolving Evidence and Treatment Strategies in Low‑Grade Serous Ovarian Cancer (LGSOC), an Industry Supported Symposium at the 2026 FSGO Annual Meeting.
This session is not included in the main event CME/CPD credit.
Brian Slomovitz, MD, M ount Sinai Medical Center
Jubilee Brown, MD, Atrium Health Wake Forest Baptisit Comprehesive Cancer Canter
Brian Slomovitz, MD, M ount Sinai Medical Center
All Faculty
All Faculty
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this internet live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.
NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Faculty Disclosures